Αρχική World News Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer World News Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer Από Ogkologos - 21 Απριλίου, 2026 258 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Exploratory 4-year Analysis Continues to Support Adding 3 Years of Ribociclib... 8 Οκτωβρίου, 2025 After Struggling With Chronic Illnesses Most of Her Life, This Author... 21 Ιουνίου, 2021 Dormant Tumor Cells Can Be Sensitized to Chemotherapy 20 Φεβρουαρίου, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Linvoseltamab 10 Απριλίου, 2025 Φόρτωση περισσοτέρων HOT NEWS EMA Recommends Granting a Marketing Authorisation for Poherdy What to Know About Mastectomy With Flat Closure After a Breast... Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic...